[{"id":"f3c62253-8046-49b1-bb25-cd529c350b91","acronym":"MORPHEUS-PDAC","url":"https://clinicaltrials.gov/study/NCT03193190","created_at":"2021-01-18T15:44:27.682Z","updated_at":"2025-02-25T16:36:54.744Z","phase":"Phase 1/2","brief_title":"A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)","source_id_and_acronym":"NCT03193190 - MORPHEUS-PDAC","lead_sponsor":"Hoffmann-La Roche","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • gemcitabine • 5-fluorouracil • Cotellic (cobimetinib) • albumin-bound paclitaxel • oxaliplatin • leucovorin calcium • Actemra IV (tocilizumab) • tiragolumab (RG6058) • etrumadenant (AB928) • pegvorhyaluronidase alfa (PEGPH20) • Aphexda (motixafortide) • selicrelumab (RG7876) • simlukafusp alfa (RG7461)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 340","initiation":"Initiation: 07/05/2017","start_date":" 07/05/2017","primary_txt":" Primary completion: 02/28/2025","primary_completion_date":" 02/28/2025","study_txt":" Completion: 02/28/2025","study_completion_date":" 02/28/2025","last_update_posted":"2025-02-06"},{"id":"5339312c-848e-4c0d-aed2-e48d851689d4","acronym":"MORPHEUS-EC","url":"https://clinicaltrials.gov/study/NCT03281369","created_at":"2021-01-18T16:12:10.112Z","updated_at":"2024-07-02T16:35:06.566Z","phase":"Phase 1/2","brief_title":"A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)","source_id_and_acronym":"NCT03281369 - MORPHEUS-EC","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2 • PD-L1 • TIGIT","pipe":" | ","alterations":" HER-2 negative • HER-2 expression","tags":["HER-2 • PD-L1 • TIGIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Tecentriq (atezolizumab) • paclitaxel • 5-fluorouracil • Cotellic (cobimetinib) • Cyramza (ramucirumab) • oxaliplatin • leucovorin calcium • tiragolumab (RG6058) • pegvorhyaluronidase alfa (PEGPH20) • Aphexda (motixafortide)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 410","initiation":"Initiation: 10/13/2017","start_date":" 10/13/2017","primary_txt":" Primary completion: 08/24/2024","primary_completion_date":" 08/24/2024","study_txt":" Completion: 04/30/2025","study_completion_date":" 04/30/2025","last_update_posted":"2024-05-01"},{"id":"6374d5b8-2750-44ab-ba42-28d9cdad5981","acronym":"","url":"https://clinicaltrials.gov/study/NCT04058964","created_at":"2021-01-18T19:53:43.999Z","updated_at":"2024-07-02T16:36:48.674Z","phase":"Phase 2","brief_title":"Pembrolizumab and PEGPH20 in Treating Patients With Metastatic Pancreatic Cancer","source_id_and_acronym":"NCT04058964","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • pegvorhyaluronidase alfa (PEGPH20)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 02/01/2020","start_date":" 02/01/2020","primary_txt":" Primary completion: 10/31/2022","primary_completion_date":" 10/31/2022","study_txt":" Completion: 10/31/2022","study_completion_date":" 10/31/2022","last_update_posted":"2020-03-13"},{"id":"5c5aa4fc-2e85-4ffd-8e85-4c95af2d9d45","acronym":"","url":"https://clinicaltrials.gov/study/NCT02563548","created_at":"2021-01-18T12:24:47.140Z","updated_at":"2024-07-02T16:36:50.341Z","phase":"Phase 1b","brief_title":"A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid Tumors","source_id_and_acronym":"NCT02563548","lead_sponsor":"Halozyme Therapeutics","biomarkers":" PD-L1 • ALK • PD-1","pipe":" | ","alterations":" EGFR mutation • ALK positive • ALK mutation","tags":["PD-L1 • ALK • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK positive • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • pegvorhyaluronidase alfa (PEGPH20)"],"overall_status":"Completed","enrollment":" Enrollment 56","initiation":"Initiation: 10/22/2015","start_date":" 10/22/2015","primary_txt":" Primary completion: 03/26/2019","primary_completion_date":" 03/26/2019","study_txt":" Completion: 03/26/2019","study_completion_date":" 03/26/2019","last_update_posted":"2020-02-07"},{"id":"ec3fc90f-0d12-4e9a-99b7-365eca56815f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01453153","created_at":"2021-01-18T06:01:57.218Z","updated_at":"2024-07-02T16:37:04.970Z","phase":"Phase 1b/2","brief_title":"Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer","source_id_and_acronym":"NCT01453153","lead_sponsor":"Halozyme Therapeutics","biomarkers":" CA 19-9","pipe":"","alterations":" ","tags":["CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • pegvorhyaluronidase alfa (PEGPH20)"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 09/01/2011","start_date":" 09/01/2011","primary_txt":" Primary completion: 02/01/2014","primary_completion_date":" 02/01/2014","study_txt":" Completion: 05/01/2015","study_completion_date":" 05/01/2015","last_update_posted":"2018-11-30"}]